000915 Shandong Wit Dyne Health
- 33.01
- +0.26+0.79%
Shandong Wit Dyne Health News
Walter Dyne (000915.SZ) subsidiary Walter Zhixin will be dissolved and liquidated
Walter Dyne (000915.SZ) issued an announcement to review the first interim meeting of the 10th board of directors of the company in 2024...
Walter Dyne (000915.SZ): Icexin Vitamin AD drops are the company's main product
Gelonghui, May 13 | Walter Dyne (000915.SZ) said on the investor interactive platform that Ecoxin Vitamin AD drops are the company's main product and have been ranked first in the market share of similar products for many years. Using the broad influence of the “Eikexin” brand, the company has also built a series of children's health products such as “Icexin” children's nutrition products, children's health foods, and children's health products.
Shandong Wit Dyne Health Co.,Ltd. (SZSE:000915) Stock Goes Ex-Dividend In Just Three Days
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Shandong Wit Dyne Health Co.,Ltd. (SZSE:000915) is about to trade ex-dividend in the next 3 da
Walter Dyne (000915.SZ) plans to pay 20 yuan for 10 shares to be exempted from interest on May 16
Walter Dyne (000915.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Walter Dyne (000915.SZ): Net profit of 169 million yuan in the first quarter increased 3.00% year-on-year
Gelonghui, April 17 | Walter Dyne (000915.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 572 million yuan, up 1.85% year on year; net profit attributable to shareholders of listed companies was 169 million yuan, up 3.00% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 162 million yuan, up 4.99% year on year; basic earnings per share were 0.72 yuan.
We Think Shandong Wit Dyne HealthLtd's (SZSE:000915) Profit Is Only A Baseline For What They Can Achieve
Shandong Wit Dyne Health Co.,Ltd.'s (SZSE:000915) strong earnings report was rewarded with a positive stock price move. We have done some analysis, and we found several positive factors beyond the pr
Waltdyne (000915.SZ) children's drugs mainly include iKexin vitamin AD drops, edicine, desloratadine oral solution, etc.
Gelonghui, March 19 | Walter Dyne (000915.SZ) said on the investor interactive platform that the company's children's drugs mainly include iKexin vitamin AD drops, eDexin, dyne iron, dyne calcium, dyne zinc, oral rehydration solution, pediatric ibuprofen suppositories, atomoxetine hydrochloride oral solution, and desloratadine oral solution. Among them, Icexin Vitamin AD drops had the largest sales of all products. “Yikexin” is a well-known trademark in China and has been ranked first in the market share of similar products for many years.
Walter Dyne (000915.SZ): Net profit for 2023 increased 11.08% to 585 million yuan, plans to pay 10 to 20 yuan
Gelonghui, March 15 | Walter Diamond (000915.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 2,484 billion yuan, up 6.11% year on year; net profit attributable to shareholders of listed companies was 585 million yuan, up 11.08% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 571 million yuan, up 7.86% year on year; basic income per share was 2.50 yuan; it plans to distribute a cash dividend of 20 yuan (tax included) to all shareholders for every 10 shares.
There's No Escaping Shandong Wit Dyne Health Co.,Ltd.'s (SZSE:000915) Muted Earnings Despite A 26% Share Price Rise
Shandong Wit Dyne Health Co.,Ltd. (SZSE:000915) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up recently los
Shandong Wit Dyne HealthLtd's (SZSE:000915) Five-year Earnings Growth Trails the Notable Shareholder Returns
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is one path to excess returns. To wit, the Shandong Wit Dyne HealthLtd share pric
Walter Dyne (000915.SZ) Performance Report: Net profit for 2023 was 584 million yuan, up 10.82% year-on-year
Gelonghui, January 19 | Walter Dain (000915.SZ) announced the 2023 annual results report. In 2023, the company achieved total operating income of 2,474 billion yuan, up 5.68% year on year; total profit of 1,323 billion yuan, up 14.15% year on year; net profit attributable to shareholders of listed companies was 584 million yuan, up 10.82% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 564 million yuan, an increase of 6.52% year on year; basic earnings per share were 2.49 yuan.
Lacklustre Performance Is Driving Shandong Wit Dyne Health Co.,Ltd.'s (SZSE:000915) Low P/E
With a price-to-earnings (or "P/E") ratio of 12.5x Shandong Wit Dyne Health Co.,Ltd. (SZSE:000915) may be sending very bullish signals at the moment, given that almost half of all companies in China h
Walter Dyne (000915.SZ): The existing production capacity can fully meet the needs of various markets for products
GLONGHUI January 16 | Walter Dyne (000915.SZ) said on the investor interactive platform that the company's current production capacity can fully meet the needs of various markets for products.
Walterdyne (000915.SZ): The rapid growth of pediatric ibuprofen suppositories had a positive impact on the company's annual performance growth
Glonghui December 20 | Walterdyne (000915.SZ) said on the investor interactive platform on December 20 that in recent years, sales of pediatric ibuprofen suppositories have been in line with expectations, and the growth rate has been relatively good. The rapid growth of pediatric ibuprofen suppositories has had a positive impact on the company's annual performance growth, but since it previously accounted for a relatively small share of the company's drug sales, the impact is not significant at this stage.
Walterdyne (000915.SZ): Dyne Pharmaceutical obtains drug registration certificate for atomoxetine hydrochloride capsules
Glonghui December 8 | Walterdyne (000915.SZ) announced that recently, Shandong Dyne Marine Biopharmaceuticals Co., Ltd. (Dyne Pharmaceutical for short), a subsidiary of Shandong Walterdyne Health Co., Ltd., received the “Drug Registration Certificate” (certificate number: 2023S01930) for atomoxetine hydrochloride capsules issued by the State Drug Administration. This product is used to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
Walterdyne (000915.SZ): Currently, Dyne Pharmaceuticals does not produce azithromycin granules
GLONGHUI December 5: Walterdyne (000915.SZ) stated on the investor interactive platform that currently Dyne Pharmaceuticals does not produce azithromycin granules. The sales situation of pediatric ibuprofen suppositories this year has increased significantly compared to previous years. Both medical institutions and retail pharmacies sell them.
Walterdyne (000915.SZ): Dyne Pharmaceuticals products are aimed at children aged 1-3 and are administered rectally
On December 5, Walt Dyne (000915.SZ) stated on the investor interactive platform that Dyne Pharmaceutical products target children aged 1-3 and are administered rectally. They are suitable for children with fever caused by the common cold or influenza to relieve children with mild to moderate pain such as headache, arthralgia, migraine, toothache, muscle pain, and neuralgia in children.
Is Shandong Wit Dyne Health Co.,Ltd.'s (SZSE:000915) Stock's Recent Performance A Reflection Of Its Financial Health?
Shandong Wit Dyne HealthLtd's (SZSE:000915) stock up by 8.1% over the past three months. Given its impressive performance, we decided to study the company's key financial indicators as a company's l
Walterdyne (000915.SZ): Currently, the utilization rate of various production plants is high, and there is no overcapacity problem
Glonghui November 13: Some investors asked Walterdyne (000915.SZ) on the investor interactive platform, “Does this mean that there is a problem of overcapacity or low capacity utilization?” The company replied that the company made medium- to long-term construction plans for the production base in accordance with the development strategy, and that the production capacity design was in line with market expectations for the company's products. Currently, the utilization rate of various production workshops is high, and there is no overcapacity problem.
Walterdyne (000915.SZ): Intends to transfer 51% shares of Dyne Health and Dyne Hi-Tech
On October 26, Huatedyne (000915.SZ) announced that the third interim meeting of the company's 10th board of directors in 2023 deliberated and passed the “bill on the transfer of the 51% equity agreement held by Shandong Dyne Marine Biopharmaceutical Co., Ltd. to Shandong Huatdyne Health Co., Ltd. to Shandong Huatdyne Health Co., Ltd.” and the “bill on the transfer of the 51% equity agreement held by Shandong Dyne Hi-Tech Children's Pharmaceutical Research Institute Co., Ltd. to Shandong Huatdyne Health Co., Ltd.” Agree to the company's transfer of Beijing Dyne Health
Analysis
Price Target
No Data
